An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

January 31, 2005

Conditions
Crohn's Disease
Interventions
DRUG

Epanova™ (Omega-3 Free Fatty Acids)

Trial Locations (31)

11021

Long Island Clinical Research Associates, Great Neck

40292

University of Louisville, Department of Surgery, Louisville

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic, Rochester

60611

Northwestern University Medical School, Chicago

60637

University of Chicago Medical Center, Chicago

61801

Carle Clinic Association, Urbana

68503

Gastroenterology Specialties, P.C., Lincoln

30342-5006

Atlanta Gastroenterology Associates, Atlanta

27599-7032

University of North Carolina Chapel Hill, Chapel Hill

T1Y 6J4

Health Sciences Centre, Calgary

T5H 4B9

Royal Alexandra Hospital, Edmonton

T6G 2C8

University of Alberta, Edmonton

V5Z 1L5

Vancouver General Hospital, Vancouver

V6Z 1Y6

St. Paul's Hospital, Vancouver

R3A 1R9

Health Sciences Centre, Winnipeg

B3H 1V7

Victoria General Hospital, Halifax

N6A 4G5

London Health Sciences Centre (South Street Campus), London

N6A 5A5

London Health Sciences Centre (University Campus), London

K1Y 4E9

The Ottawa Hospital (Civic Campus), Ottawa

M4N 3M5

Sunnybrook & Women's College HSC, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

G1L 3L5

CHUQ - Pavillon St-François d'Assise, Montreal

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

H2X 3J4

Hôpital Saint-Luc, Montreal

H3A 1A1

Royal Victoria Hospital, Montreal

H3G 1A4

Montreal General Hospital, Montreal

H3T 1E2

Jewish General Hospital, Montreal

G1R 2J6

CHUQ-Hôtel-Dieu de Québec, Québec

G1S 4L8

Hôpital St-Sacrement, Québec

All Listed Sponsors
lead

Tillotts Pharma AG

INDUSTRY

NCT00074542 - An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease | Biotech Hunter | Biotech Hunter